SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Monday, June 6, 2016

Naveen Pemmaraju, MD, discusses early results from an ongoing trial of SL-401 in patients with the rare, aggressive malignancy blastic plasmacytoid dendritic cell neoplasm.

October 2018, Volume 4, Issue 12

Focus on Classical Hematology (Volume 4, Issue 12.1)

September 2018, Volume 4, Issue 11

August 2018, Volume 4, Issue 10

SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Recent Articles

Pulling Back the Curtain: Vip Viprakasit, MD, DPhil

Let’s Get Cooking: Jonathan Hoggatt, PhD

Pulling Back the Curtain: Richard W. Childs, MD

Examining Hospice Use Among Transfusion-Dependent Patients With Leukemia

Pulling Back the Curtain: Richard W. Childs, MD

Current Issue

October 2018, Volume 4, Issue 12

Meeting Coverage

LentiGlobin Gene Therapy Possibly Safe for Severe Sickle Cell Disease

How Do Patient and Physician Attitudes Drive Choices in Antiplatelet Therapy for Thrombocytopenia?

Editor`s Corner

Draining the Email Swamp

Recommendations from My Bookshelf: A Bloody Mess